Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8291369 | 0.85 | ALDH1A1 (0.44) | ALDH1A1RECQLPOLBGAATSHR | |
| SCHEMBL10064150 | 0.82 | ALDH1A1 (0.60) | ALDH1A1RECQLPOLBGAATSHR | |
| SCHEMBL30218661 | 0.75 | POLB (0.54) | ALDH1A1POLBTSHRMEN1KMT2A | |
| SCHEMBL19265679 | 0.67 | ALDH1A1 (0.62) | ALDH1A1RECQLPOLBGAATSHR | |
| SCHEMBL66294 | 0.66 | SMN1; SMN2 (0.63) | MEN1KMT2ALMNAHTTSMN1; SMN2 | |
| SCHEMBL2885907 | 0.65 | HTT (0.55) | ALDH1A1POLBTSHRKMT2ALMNA | |
| SCHEMBL21200181 | 0.64 | NPC1 (0.73) | ALDH1A1RECQLGAATSHRMEN1 | |
| SCHEMBL229324 | 0.62 | MEN1 (0.78) | ALDH1A1POLBMEN1KMT2ALMNA | |
| SCHEMBL28837689 | 0.62 | RAB9A (0.65) | POLBGAAMEN1KMT2ALMNA | |
| SCHEMBL3373218 | 0.62 | SMN1; SMN2 (0.42) | ALDH1A1MEN1KMT2ALMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7705031-B2 | Benzimidazoles useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-27 | — | — | US | disclosed |
| US-20080306129-A1 | BENZIMIDAZOLES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2008-12-11 | — | — | US | disclosed |
| US-7309716-B2 | Benzimidazoles useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-12-18 | — | — | US | disclosed |
| WO-2005042497-A2 | BENZIMIDAZOLES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306129-A1 | BENZIMIDAZOLES USEFUL AS MODULATORS OF ION CHANNELS | KCNJ11, KCNJ1, KCNJ2 | ALDH1A1 484/4885RECQL 680/4885POLB 4746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.